相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Adalimumab induction therapy for Crohn disease previously treated with infliximab - A randomized trial
William J. Sandborn et al.
ANNALS OF INTERNAL MEDICINE (2007)
A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease
Bruce Yacyshyn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
ICAM-1-dependent pathways regulate colonic eosinophilic inflammation
Elizabeth Forbes et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2006)
A Phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis
SJH Van Deventer et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial
PB Miner et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis
PB Miner
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Natalizumab induction and maintenance therapy for Crohn's disease
WJ Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1
BR Yacyshyn et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2005)
Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin
BG Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs
HJ Wu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
P Rutgeerts et al.
GASTROENTEROLOGY (2004)
An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis
P Miner et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice
SP Henry et al.
BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY (2004)
Effects of an antisense oligonucleotide inhibitor of human ICAM-1 on fetal development in rabbits
SP Henry et al.
BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY (2004)
A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis
SJH van Deventer et al.
GUT (2004)
Progress in antisense technology
ST Crooke
ANNUAL REVIEW OF MEDICINE (2004)
Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences
EV Loftus
GASTROENTEROLOGY (2004)
A novel targeted T-cell modulator, efalizumab, for plaque psoriasis
M Lebwohl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease
BR Yacyshyn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2002)
Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease
BR Yacyshyn et al.
GUT (2002)
Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease
S Schreiber et al.
GASTROENTEROLOGY (2001)
Changed colonic profile of P-selectin, platelet-endothelial cell adhesion molecule-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), ICAM-2, and ICAM-3 in inflammatory bowel disease
B Vainer et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2000)
分享论文
